Medtronic Raises 2027 Forecasts Amid Heart Device Surge

Medtronic has revised its fiscal 2027 projections upward, citing robust demand for its heart devices used in complex cardiovascular procedures. The company now anticipates annual organic revenue growth of 7.25% to 7.75%, an increase from its previous forecast of 6.75% to 7.25%. Additionally, Medtronic adjusted the lower end of its per-share profit forecast from $5.90 to $5.94, maintaining the upper limit at $6.

Strategic Investments and Acquisitions

In a strategic move, Medtronic announced an $80 million investment in Pi-Cardia, a company specializing in heart-valve repair devices, with an option to acquire it for $210 million. Furthermore, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in certain markets outside of the United States. CEO Geoff Martha noted that the penetration of soft tissue robotic surgery in emerging markets remains below 1%, highlighting the potential for growth.

Financial Performance and Market Confidence

Medtronic's latest financial results underscore its strong market position. The company's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by an 88% increase in its pulsed field ablation portfolio, utilized for treating irregular heart rhythms. Overall, Medtronic's quarterly revenue stood at $9.76 billion, surpassing expectations of $9.55 billion, with an adjusted per-share profit of $1.45 compared to the anticipated $1.39.

Medtronic's CFO, Thierry Pieton, revealed that the company received tariff refunds nearly covering the duties paid during the quarter, although future refunds have not been factored into the company's outlook. CEO Martha emphasized the company's focus on high-growth segments within the medical technology sector, targeting large patient pools and substantial market opportunities.